MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• MicroRNA Therapeutics

Background:

• Myocardial infarction (MI) induces complex molecular changes, including microRNA dysregulation.
• Identifying specific microRNAs involved in post-MI cardiac remodeling is crucial for developing targeted therapies.

Purpose of the Study:

• To identify novel cardiac microRNAs aberrantly expressed after MI in a rat model.
• To investigate the role of miR-31 in adverse cardiac remodeling post-MI.
• To evaluate the therapeutic potential of inhibiting miR-31 in vivo.

Main Methods:

• MicroRNA array profiling and quantitative real-time PCR in rat hearts post-MI.
• Reporter gene assays to confirm miR-31 targets.
• In vitro studies using cardiac cell cultures under hypoxic and oxidative stress.
• In vivo therapeutic administration of a miR-31 inhibitor (miR-31i) in a rat MI model.

Main Results:

• miR-31 was significantly and progressively upregulated in the infarcted myocardium post-MI.
• miR-31 was confirmed to target cardiac troponin-T (Tnnt2), E2f6, Nr3c2, and Timp4.
• In vitro, hypoxia and oxidative stress increased miR-31 and suppressed its targets.
• In vivo, miR-31i treatment preserved cardiac structure and function, improving ejection fraction and reducing infarct size and fibrosis.

Conclusions:

• miR-31 induction post-MI is detrimental to cardiac function.
• Therapeutic inhibition of miR-31 ameliorates cardiac dysfunction and prevents adverse post-ischemic remodeling.
• Targeting miR-31 represents a promising therapeutic strategy for managing myocardial infarction.